Impact of surveillance on survival after laryngeal cancer in the medicare population
β Scribed by David O. Francis; Bevan Yueh; Ernest A. Weymuller Jr.; Albert L. Merati
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 184 KB
- Volume
- 119
- Category
- Article
- ISSN
- 0023-852X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Objectives/Hypothesis:
Routine surveillance is advocated to detect recurrent disease after treatment for laryngeal cancer. This aim of this study was to determine the 1β and 5βyear postrecurrence mortality for laryngeal cancers and evaluate whether more intensive surveillance improved survival.
Study Design:
Retrospective cohort study.
Methods:
Patients with recurrent cancers (1992β1999) were identified in a national cancer clinical database. Multivariate analysis was used to evaluate the effect of surveillance on postrecurrence survival.
Results:
Of 2,121 recurrent cancers identified, 913 were laryngeal. Patients with laryngeal cancer recurrence had 27% (P = .001) and 22% (P = .007) better odds of 1β and 5βyear survival than other sites. The 1β and 5βyear postrecurrence survival rates for laryngeal cancer patients were 72.4% and 41.3%, respectively. Glottic cancer cases had the best postrecurrence life expectancy. Multivariate regression revealed that clinical surveillance intensity had no independent impact on their survival (P < .05). However, patients with recurrent glottic cancer seen in surveillance had 23% improved odds of survival (P = .037).
Conclusions:
More frequent surveillance visits was not associated with a survival advantage in the overall population. Patients with glottic cancer had a postrecurrence survival advantage if seen during the surveillance period. Laryngeal cancer patients had better postrecurrence survival than other head and neck sites. Laryngoscope, 2009
π SIMILAR VOLUMES
## Abstract ## BACKGROUND: Sunitinib has replaced interferon (IFN) as a firstβline standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. ## METH
## Abstract ## BACKGROUND. Over the past decade, a number of new therapeutic agents have become available in the treatment of metastatic breast cancer (MBC). This study characterized the use and assessed the impact on survival of populationβbased access to new agents for the treatment of MBC. ##